{"Clinical Trial ID": "NCT01300351", "Intervention": ["INTERVENTION 1:", "Fulvestant 500 mg", "- Furvestant 500 mg intramuscular (im) every 28 (\u00b1 3) days plus 500 mg extra on day 15 (\u00b1 3) of the first month only", "INTERVENTION 2:", "-Fulvestant 250 mg", "- Furvestant 250 mg once every 28 (\u00b1 3) days"], "Eligibility": ["Incorporation criteria:", "Menopausal women defined as a woman who has ceased to have menstruation", "Breast cancer continued to grow after receiving hormonal anti-estrogen therapy such as tamoxifen or an aromatase inhibitor.", "- Requires hormonal treatment", "Positive oestrogen-receptor tumour", "Informed written consent to participation in the trial", "- Exclusion criteria:", "- Treatment with an experimental or unapproved medicine within one month", "\u2022 An existing disease, disease or serious condition that will prevent participation or compliance with study procedures", "\u2022 History of allergies to any active or inactive ingredient of the flulvestrant (i.e. castor oil)", "Treatment with more than one advanced breast cancer chemotherapy regimen", "Treatment with more than one hormonal treatment regimen for advanced breast cancer"], "Results": ["Performance measures:", "- Survivors without progression", "The progression is defined using the criteria for assessing the response in the solid tumour criteria (RECIST v1.1), such as an increase of at least 20% in the sum of the diameters of the target lesions, taking as a reference the smallest sum on the study, or an unequivocal progression of existing non-target lesions, or the appearance of new lesions, or death (by any cause in the absence of progression).", "Time limit: 36 months", "Results 1:", "Title of the arm/group: Fulvestant 500 mg", "Description of the arm/group: Fulvestant 500 mg intramuscular (im) every 28 ( 3) days plus an additional 500 mg on day 15 ( 3) of the first month only", "Total number of participants analysed: 111", "Median (interquartile range)", "Unit of measure: month 8.0 (2.8 to 16.6)", "Results 2:", "Title of arm/group: Fulvestant 250 mg", "Description of the arm/group: Fulvestant 250 mg im every 28 ( 3) days", "Total number of participants analysed: 110", "Median (interquartile range)", "Unit of measure: month 4.0 (2.7-11.1)"], "Adverse Events": ["Undesirable Events 1:", "Total: 4/109 (3.67 per cent)", "Anemia * 0/109 (0.00 %)", "Uremic haemolytic syndrome * 0/109 (0.00 %)", "Leucopenia * 0/109 (0.00 %)", "Heart failure * 0/109 (0.00 %)", "Pyrexia * 1/109 (0.92%)", "Abnormal liver function * 1/109 (0.92%)", "Bacterial Arthritis * 0/109 (0.00 %)", "\u2022 Pulmonary infection * 0/109 (0.00 %)", "Decreased haemoglobin * 1/109 (0.92%)", "Decrease in neutrophil count * 0/109 (0.00 %)", "Adverse Events 2:", "Total: 9/110 (8.18 per cent)", "Anemia * 1/110 (0.91%)", "Hemolytic ureaemic syndrome * 0/110 (0.00 %)", "Leucopenia * 0/110 (0.00 %)", "* 1/110 (0.91%)", "Pyrexia * 2/110 (1.82%)", "Abnormal liver function * 0/110 (0.00 %)", "Bacterial Arthritis * 2/110 (1.82%)", "\u2022 Pulmonary infection * 0/110 (0.00 %)", "Decreased haemoglobin * 1/110 (0.91%)", "Decrease in neutrophil count * 0/110 (0.00 %)"]}